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SUMMARY
Selective serotonin [5-hydroxytryptamine (5-HT)] reup-
take inhibitors (SSRIs) and the 5-HT noradrenaline reup-
take inhibitor, venlafaxine, are mainstays in treatment for
depression. The highly specific actions of SSRIs of enhan-
cing serotonergic neurotransmission appears to explain
their benefit, while lack of direct actions on other neuro-
transmitter systems is responsible for their superior safety
profile compared with tricyclic antidepressants. Although
SSRIs (and venlafaxine) have similar adverse effects, certain
differences are emerging. Fluvoxamine may have fewer
effects on sexual dysfunction and sleep pattern. SSRIs
have a cardiovascular safety profile superior to that of
tricyclic antidepressants for patients with cardiovascular
disease; fluvoxamine is safe in patients with cardiovascular
disease and in the elderly. A discontinuation syndrome
may develop upon abrupt SSRI cessation. SSRIs are more
tolerable than tricyclic antidepressants in overdose, and
there is no conclusive evidence to suggest that they are
associated with an increased risk of suicide. Although the
literature suggests that there are no clinically significant
differences in efficacy amongst SSRIs, treatment decisions
need to be based on considerations such as patient accept-
ability, response history and toxicity.
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INTRODUCTION
Over the years, there have been considerable advances in
the development of new antidepressants with the emer-
gence of the selective serotonin [5-hydroxytryptamine (5-
HT)] reuptake inhibitors (SSRIs) and 5-HT noradrenaline
reuptake inhibitors (SNRIs). Since their introduction, it
has become apparent that these drugs have certain advan-
tages over the older tricyclic antidepressants and monoa-
mine oxidase inhibitors, notably in the area of safety and
tolerability. Most clinicians now consider the SSRIs and
some of the other new antidepressants first-line treatment
for depression and anxiety disorders. However, the issue of
safety and tolerability, and indeed efficacy, becomes more
complex when comparing members of the newer genera-
tions of antidepressants. Not only are SSRIs chemically
different from the tricyclic, tetracyclic and other antide-
pressant agents, considerable structural differences also
exist between the various SSRIs. For example, fluvoxamine
is the only monocyclic SSRI and belongs to the 2-ami-
noethyl oxime ethers of aralkylketones. Therefore, some
differential pharmacology between the drugs in the same
class may be expected. The aim of this review, which was
b a s e do naM e d l i n el i t e r a t u r es e a r c h ,i st op r o v i d ea
comprehensive comparative overview of the main clinical
features of some antidepressants based on pharmacology,
pharmacokinetics, tolerability and safety.
PHARMACOLOGIC AND PHARMACOKINETIC
ASPECTS
Receptor Binding
Most of the effects of antidepressants, whether therapeutic or
adverse, can be directly related to their pharmacology.
Although the ultimate mechanism of action of antidepressants
remains uncertain, it is reasonable to assume that the effects
on monoamine systems in the brain are central to their
therapeutic effects. SSRIs attain this effect by blocking the
5-HT transporters (5-HTTs) in the brain. Although this is
the primary pharmacological effect of all SSRIs, their spec-
trum of activity is not confined to the blockade of 5-HTT.
Venlafaxine, for instance, is one of the most potent antide-
pressants at blocking the dopamine transporter, and paroxe-
tine, although the most potent blocker of 5-HTT, also has
appreciable affinity for the noradrenaline transporter (NAT)
(1). In general, SSRIs are weaker than older antidepressants
(especially the tricyclic antidepressants) at blocking receptors
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a1-adrenoreceptor, paroxetine has anticholinergic properties
similar to imipramine, and fluoxetine has significant affinity
for the 5-HT2C receptor (2–6).
In comparison with the other SSRIs, paroxetine has the
highest affinity for the muscarinic receptor (Figure 1) (1),
which at higher dosages, or at low dosages in slow metabolisers,
may lead to anticholinergic side effects such as dry mouth,
constipation, dizziness, tachycardia, blurred vision, urinary
retention and fatigue (7). Anticholinergic side effects also
include memory impairment (7,8), confusion (7), problems
with concentration (7) and sexual dysfunction, but these side
effects are less likely to occur at normal dosages of paroxetine
(9–12). Compared with other antidepressants, paroxetine also
has an affinity for binding at the NAT (Figure 2) (1).
Of all the SSRIs, citalopram has the highest affinity at hista-
mine receptors (Figure 3). This property, which may cause
somnolence (13), sedation (13,14), sexual dysfunction (10),
weightgain(15,16),memoryimpairment (17), attention deficit
(17) and psychomotor alterations (18,19), has no or only minor
clinical significance for citalopram at normal dosages.
Fluvoxamine has virtually no affinity for any of the above
receptors, but preclinical evidence suggested that fluvoxamine
hasahighaffinityforthes1-receptor,whichisbelievedtoplaya
roleinpsychosis and aggression.Asshown inFigure 4,ofallthe
SSRIs, fluvoxamine has the highest affinity at the s1-receptor in
rat brain, followed by sertraline, fluoxetine and citalopram.
Paroxetine has the lowest affinity for this binding site (20). All
SSRIs are more selective for the s1-receptor than for the s2-
receptor. Although the clinical significance of binding to this
receptor remains uncertain, it might account for the superior
efficacy of fluvoxamine in psychotic depression (21,22).
Half-Life and Active Metabolites
The half-lives of fluvoxamine, paroxetine, sertraline and cita-
lopram are all approximately 1 day. The half-life of fluoxetine
is approximately 2 days after a single dose and 6 days after
multiple dosing (23). The half-life of venlafaxine is relatively
short (about 4 h), and hence this drug requires twice daily
(b.i.d.) or three times daily dosing (24); the extended-release
formulation (venlafaxine XR) permits once-daily dosing.
Fluoxetine has a pharmacological active metabolite, nor-
fluoxetine, which has a half-life of 7–15 days (23–25).
Sertraline also has an active metabolite (26), citalopram has
three active metabolites (27), and escitalopram has two (28).
Of the seven metabolites identified from venlafaxine, at least
three of them are pharmacologically active (18).
A long half-life of the parent compound or the presence of
active metabolites may cause accumulation, which is asso-
ciated with an increased risk of late-emergent side effects,
may be cardiotoxic (especially in case of overdose) and may
have clinically unexpected consequences (29).
The significant longer half-lives of fluoxetine and its metabo-
lite, norfluoxetine, are associated with a significantly slower onset
of action in comparison with other SSRIs (29). A double-blind
study comparing SSRIs in patients with depression have shown
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Figure 1 Relative potency of the antidepressants for binding at
muscarinic receptors. Potency of antidepressants for binding at
muscarinic receptors based on IC50 values: fluvoxamine, 34,000;
venlafaxine, 11,000; citalopram, 5600; fluoxetine, 3100; sertraline,
1100; paroxetine, 210 (1)
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Figure 2 Relative potency of the antidepressants for binding at the
noradrenaline transporter. Potency of antidepressants at noradrena-
line transporter based on IC50 values: citalopram, 6100; desmethyl-
citalopram, 740; fluvoxamine, 620; venlafaxine, 620; fluoxetine,
370; sertraline, 160; paroxetine, 81 (1). *Active member of
citalopram
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Figure 3 Relative potency of the antidepressants for binding his-
taminergic (H1) receptors. Potency of antidepressants for binding
H1 receptors based on Ki values: fluvoxamine (1), 29,250; parox-
etine (1), 23,770; venlafaxine (5), 11,000; sertraline (1), 6578;
fluoxetine (1), 1548; citalopram (1), 283 (15)
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action compared with fluvoxamine (30). In fact, a slower onset
of action with fluoxetine compared with the other SSRIs has been
reported in a recent meta-analysis of 20 comparative studies (31).
Moreover, the gradual accumulation of norfluoxetine may pro-
duce a high ratio of norfluoxetine : fluoxetine plasma concentra-
tion, which is associated with a poor clinical response (32,33).
This elevated norfluoxetine : fluoxetine ratio may also explain the
loss of therapeutic efficacy sometimes observed in long-term
treatment with fluoxetine (34).
With the possible exception of citalopram, SSRIs are rela-
tively safe in cases of overdose (35–37). Citalopram’s active
metabolite, didesmethylcitalopram, has played an important
role in several cases of cardiotoxicity (29), because it may
cause a QT prolongation (35,37,38). After discontinuation,
residual amounts of fluoxetine and norfluoxetine in the plasma
may increase the potential toxicity of subsequent TCA over-
dose due to pharmacokinetic drug–drug interactions (39).
It is worth noting that the metabolites of sertraline (des-
methylsertraline), fluoxetine (norfluoxetine) and paroxetine
all inhibit cytochrome P (CYP)450 isoenzymes, notably
CYP 2D6 (23). Although CYP 2D6 makes up only about
2–5% of the total CYP in the human liver, it is a major
enzyme catalysing the oxidation of more than 30 drugs (40).
Protein Binding
The plasma protein binding of the SSRIs ranges from about
50% up to 99%. Fluvoxamine and citalopram have the lowest
plasma protein binding of all SSRIs, of 77% and 50%,
respectively (23). Venlafaxine has the lowest protein binding
of all modern antidepressants with a binding of 27% (24).
Although this issue is considered of minimal clinical signifi-
cance, there are reports of important adverse events related to
protein-binding displacement interactions (41).
CYP450 2D6 Drug Metabolising Enzymes
The interactions related to CYP liver enzymes may have no
effect, lead to intoxication or improve the therapeutic
response of a given agent. The different pharmacokinetic
profiles of the antidepressants, especially their potential for
drug–drug interactions, should always be considered espe-
cially when multiple drugs are prescribed (42).
The CYP 2D6 subenzyme metabolises numerous drugs,
including many typical and atypical antipsychotics (e.g.
risperidone), antiarrhythmics (e.g. flecainide), tricyclic
antidepressants (e.g. imipramine and amitryptiline), anti-
hypertensive drugs (e.g. some b-blockers) and codeine
(43–45). Interindividual variation in the gene that encodes
CYP 2D6 plays an important role in the variable drug treat-
ment responses (44). About 5–10% of all Caucasians lack a
functional CYP 2D6 enzyme and are phenotypically poor
metabolisers (44). Conversely, about 5% are ultra-rapid meta-
bolisers, resulting in rapid biotransformation of antidepres-
sants. In fact, CYP 2D6 polymorphisms may contribute to
development of adverse effects or may be a reason for the
poor efficacy of antidepressant treatment (46).
Paroxetine and fluoxetine (and norfluoxetine) are very
potent inhibitors of CYP 2D6 (42,47–49). Of all SSRIs,
fluvoxamine has the lowest potential for drug interactions
involving this enzyme (43).
CYP 2D6 may play a minor in the metabolism of citalo-
pram, but one of its main metabolites, N-desmethylcitalo-
pram, is further extensively metabolised by CYP 2D6 to
didesmethylcitalopram (45,50). Indeed, in a recent publica-
tion, pharmacokinetic interactions were found for citalopram
due to CYP 2D6 (50). The interactions with CYP 2D6 may
be clinically significant not only for citalopram but also for
escitalopram (51).
CYP 2D6 is the major enzyme involved in the metabolism
of venlafaxine (52). Although venlafaxine is considered by
some investigators to be a weak inhibitor of CYP 2D6 (43),
CYP 2D6 plays an important role in the formation of O-
desmethylvenlafaxine that is one of venlafaxine’s major meta-
bolites (53). Decreased CYP 2D6 activity has been associated
with cardiovascular toxicity observed during treatment with
venlafaxine (54).
Fluvoxamine inhibits CYP 1A2, CYP 2C19 and CYP 3A3/
4 (55–57). Fluoxetine substantially inhibits CYP 2D6, CYP
3A3/4, CYP 2C9 and CYP 2C19 (55,56,58); its active meta-
bolite, norfluoxetine, inhibits CYP 3A3/4, CYP 2C19 and
CYP 2B6 (59).
As the effect of the SSRIs on hepatic CYP450 enzymes
differ markedly and may be clinically important, selection of
the antidepressant should be appropriate for the patient (59).
TOLERABILITY
Gastrointestinal Adverse Events
The most common adverse event reported during treatment
with SSRIs is nausea, which tends to disappear after some
Fluvoxamine Fluoxetine Sertraline Paroxetine Citalopram
Figure 4 Relative affinity for s1-receptors. Affinities of selective
serotonin reuptake inhibitors for the subtypes of s-receptors (Ki
ratio s1/s2) (20)
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similar for all SSRIs (61), occurring quite frequently as a
consequence of increased availability of 5-HT in the gastro-
intestinal tract and also probably in central nervous system.
Stimulation of 5-HT3 receptors plays a pivotal role in the
development of this side effect, as antagonists for this receptor
are capable of reducing the effect (62). Nausea is also among
the most common adverse reactions for venlafaxine (63,64).
Recently, sertraline has been shown to cause statistically sig-
nificantly more diarrhoea than other SSRIs (p < 0.05) (65).
Sexual Dysfunction
Depressed male patients are almost twice as likely to present
with erectile dysfunction compared with non-depressed men
(66). Furthermore, patients treated with an SSRI may present
with sexual dysfunction as an unwanted side effect of therapy.
Paroxetine, sertraline and citalopram are reported to cause
delayed ejaculation. A double-blind, randomised comparative
study in 60 patients with premature ejaculation showed that
placebo and fluvoxamine had no effect on the ejaculation
time after 6 weeks of treatment, while paroxetine, fluoxetine
and sertraline all significantly (p < 0.05) increased ejacula-
tion latency; the greatest effect was seen with paroxetine (67).
The SSRIs are reported to cause sexual dysfunction in the
following descending order of frequency: paroxetine, fluoxe-
tine, citalopram, sertraline and fluvoxamine (66). This is
confirmed in part in a direct double-blind comparison
between fluvoxamine and sertraline in which the incidence
of abnormal ejaculation and decreased libido was significantly
(p < 0.05) higher with sertraline than with fluvoxamine (68).
In addition, in several studies in which patients were specifi-
cally interviewed with a sexual dysfunction questionnaire,
orgasm/ejaculation delay and impotence were reported signif-
icantly more frequently with paroxetine than with other
SSRIs (69,70).
The SNRI, venlafaxine, has been associated with impo-
tence, abnormal ejaculation and orgasm, especially at higher
doses, and it is reported to have an incidence of sexual side
effects at least as high as that seen with paroxetine and sertra-
line (71).
Sexual side effects should be taken into consideration
before prescribing a drug treatment for depression, because
sexual dysfunction may play an important role in compliance
with treatment and can act as an additional stress factor for
the patient (72).
Central Nervous System Impairment
In contrast to the tricyclic antidepressants, SSRIs at normal
clinical doses have little effect on cognitive psychomotor
functioning. However, sertraline, paroxetine and fluoxetine
have all shown some alerting effects and excitation (73,74)
that may be detrimental in elderly patients. Indeed, fluoxetine
has been reported to be associated with an increased incidence
of nervousness and insomnia compared with the tricyclic
antidepressants (75,76). Paroxetine has also been shown to
impair cognition and vigilance, which may also be particularly
problematic in elderly patients (77).
Drug-induced behaviour arousal features in activation, over
motivation, pathological anxiety, compromised sexual func-
tion and cognitive impairment (78). In contrast to sertraline,
paroxetine and fluoxetine, fluvoxamine has been shown to
have little or no effect on behavioural arousal (78). Indeed,
fluvoxamine has no effect on psychomotor speed, cognitive
processing or arousal (73). Similarly, fluvoxamine showed no
potentiation of alcohol-related cognitive impairment (79). As
fluvoxamine (50 mg and 100 mg) was found not to impair
psychomotor performance or cognitive ability in any relevant
tests, including choice reaction time, tracking, critical flicker
fusion threshold and memory scanning, it may be of value
for use in outpatients who wish to carry out the tasks of
everyday life.
In a double-blind study comparing dothiepin and venla-
faxine in elderly patients, venlafaxine 37.5 mg administered
b.i.d. did not have any negative effect on cognitive function
and psychomotor performance (80). However, venlafaxine
75 mg/day is not considered to be the usual effective venla-
faxine dose for the treatment of major depression.
Sleep Quality
Evidence suggests that fluvoxamine has beneficial effects on
sleep in depressed patients. A recent double-blind study com-
paring fluvoxamine and fluoxetine showed that depressed
patients treated with fluvoxamine improved their sleep quality
both significantly more and more rapidly than patients on
fluoxetine (81). Another direct comparative study involving
fluvoxamine and paroxetine (72) showed that paroxetine
caused a greater disruption of sleep patterns than fluvoxa-
mine, and the paroxetine-induced sleep disruption persisted
into the withdrawal phase (82).
The beneficial effects of fluvoxamine on sleep quality have
also been reported in patients with post-traumatic stress dis-
order (PTSD). Fluvoxamine was effective in reducing all three
symptom clusters of PTSD (intrusion, avoidance and hyper-
ardusal), including nightmares and insomnia (83). In addi-
tion, patients suffering from other anxiety disorders, such as
obsessive-compulsive disorder and panic disorder, have been
found to experience a significant reduction of insomnia when
treated with fluvoxamine (84). It has been suggested that the
beneficial effects of fluvoxamine on sleep may be related to its
inhibitory effect on melatonin degradation; this effect has not
been observed with other SSRIs (85,86).
In a double-blind placebo-controlled study, venlafaxine was
found to decrease sleep continuity, markedly increase the time
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duration of total REM sleep (87). Other more recent
publications confirm that venlafaxine worsens sleep quality
(88–90).
Bodyweight
Changes in bodyweight are associated with a low acceptance
of treatment and an increased risk of non-compliance during
long-term treatment by patients (91). Typically, SSRIs med-
iate a reduction in food intake, particularly in the initial phase
of therapy. However, weight is frequently regained after 6
months of treatment and can be followed by additional
weight gain during long-term treatment (92).
Paroxetine, fluoxetine, citalopram and sertraline have been
shown to significantly increase bodyweight after 6–12 months
of administration (93). Weight gain could be related to
carbohydrate craving, as reported for citalopram (94).
However, an alteration in metabolic rate may be responsible
for the weight changes (95). In this regard, fluvoxamine was
reported to promote an increase in resting metabolic rate,
resulting in less weight gain (95). Of the SSRIs, paroxetine
may be responsible for the highest amounts of weight gain
(92,93). However, follow-up over 2 years of patients receiving
open-label clomipramine, citalopram, fluoxetine, fluvoxa-
mine, paroxetine or sertraline showed that clomipramine
was associated with the highest weight increase and fluoxetine
and sertraline with the lowest (96).
Weight changes observed with SSRIs appear to involve the
interaction of 5-HT with multiple mechanisms, with the
extent of weight gain being dependent on small, yet pharma-
cological important differences in this class of antidepressants
(97). Venlafaxine, such as fluoxetine, at least in short term,
reduces food intake (98,99).
SAFETY
Safety in Special Populations
Patients with cardiovascular impairment. The SSRIs are more
suitable than the tricyclic antidepressants for the treatment of
patients with cardiovascular and cerebrovascular diseases
(both of which are associated with a high incidence of depres-
sion) due to their superior cardiovascular safety profile.
Evidence for the safety of fluoxetine, sertraline and paroxetine
has been inferred from cardiac effects in healthy volunteers,
while sertraline has also been used safely in patients with
recent myocardial infarctions or unstable angina (100). A
review of the citalopram database found that the majority of
patients with abnormal ECGs had pre-existing cardiac disease
or were receiving medication likely to affect the QTc interval
(101). Fluvoxamine has been widely studied in patients with
cardiovascular impairment, and evidence suggests it has no
effect on cardiovascular function in physically healthy
patients and is safe in patients with cardiovascular disease
(102–107).
In contrast, venlafaxine causes increases in heart rate and
blood pressure in some patients (108). In a sample of 3744
depressed patients treated with venlafaxine, a dose-dependent
elevation of supine diastolic blood pressure was reported that
was statistically and clinically significant, especially in doses
above 300 mg/day (108). An overall tendency to mildly
raised blood pressure may be apparent in 10% of individuals
on venlafaxine, regardless of the daily dose (109).
Hypertensive crises have also been reported for venlafaxine
(110). Regular blood pressure monitoring is advised in
patients receiving venlafaxine while discontinuation is recom-
mended in patients with a sustained elevation. Indeed, pre-
liminary evidence suggests that venlafaxine may be an
effective treatment in patients with severe orthostatic hypo-
tension (111).
Elderly patients. The good safety profile of the SSRIs in
comparison with the tricyclic antidepressants is particularly
important when treating elderly patients. Differences in the
safety and tolerability profile between the SSRIs suggest that
some may be more suitable than others for the treatment of
elderly patients. Fluoxetine, for example, is associated with
nervousness (112–114) and insomnia (114), which suggests
that it should be employed with caution in frail, elderly
patients. It should also be noted that although considerable
interindividual variation exists, higher plasma levels of parox-
etine have been observed in elderly patients along with its
reduced elimination.
The clearance of citalopram has also been observed to
generally decrease with increasing age (115); a dose reduction
or close monitoring is therefore advised for the elderly patient
taking citalopram.
The excellent safety profile of fluvoxamine in the
elderly, without the need of dose adjustments, was con-
firmed in an analysis of data from 4843 patients (mainly
depressed) aged 65–97 years enrolled in world-wide post-
marketing studies conducted over periods of up to 1 year
(116). Findings from a study in 137 elderly patients aged
between 75 and 97 years (mean 81 years), who also had a
high incidence of concomitant illnesses and requirement
for other medications, have also confirmed the excellent
safety of fluvoxamine (117).
Treatment-emergent hypertension may occur in a small
percentage of older patients taking venlafaxine in doses
above 150 mg/day (118), and thus careful monitoring of
these patients is advisable.
Discontinuation Symptoms
Discontinuation symptoms upon abrupt withdrawal have
been reported for all SSRIs (119), although it is now evident
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than with the other SSRIs. An evaluation of the UK post-
marketing surveillance database of adverse reactions revealed
more reports of discontinuation symptoms with paroxetine
(0.3 reports per 1000 prescriptions) than sertraline (0.03) or
fluvoxamine (0.03), and the least with fluoxetine (0.002)
(120).
In a double-blind, placebo-controlled study specifically
designed to assess the effects of interruption of fluoxetine,
sertraline or paroxetine treatment, placebo substitution for
paroxetine was associated with an increase in the number
and severity of adverse events following the second missed
dose and increases in functional impairment at 5 days (121).
Effects were considerably less marked with the other SSRIs.
Similar findings were reported in another double-blind, pla-
cebo-controlled trial in which treatment with paroxetine,
fluoxetine, sertraline or citalopram was suddenly interrupted
for 4–7 days (122). Interruption of paroxetine was associated
with significantly more cognitive problems and poorer quality
of sleep.
Neonatal withdrawal syndrome has also been reported
after in utero exposure to paroxetine (123), while high rates
of neonatal complications in women exposed to paroxetine
during the third trimester of pregnancy have been possibly
attributed to the withdrawal syndrome (124).
Of the top 20 medicines in UK with reports of symptoms
of withdrawal entered on to the British ADROIT database
(125), paroxetine was at the top of the list with 1281 reports.
Venlafaxine occupied the second position with 272 reports,
while fluoxetine, sertraline and citalopram were fourth, fifth
and sixth, respectively. Fluvoxamine was placed 19th
(Table 1). It appears that a long drug half-life delays the
onset of discontinuation symptoms rather than preventing
them. A review of the literature found that the mean length
of time for the appearance of discontinuation symptoms was
6.4 days with fluoxetine compared with 2–4 days for sertra-
line, fluvoxamine and paroxetine (126).
Suicide Risk
There is controversy about the possibility that SSRI antide-
pressants might induce suicidality in some patients; the role of
antidepressants in suicide prevention has therefore become a
major public health question. In a review of randomised
controlled trials, meta-analyses of clinical trials and epidemio-
logical studies, an excess of suicidal acts on active treatments
compared with placebo made it difficult to sustain the
hypothesis that SSRIs do not cause problems in some indivi-
duals (127). A more recent systematic review of randomised
controlled trials, which included 87,650 patients, also found a
significant increase in the odds of suicide attempts for patients
receiving SSRIs compared with placebo (128).
Other studies have failed to support either an overall dif-
ference in suicide risk between antidepressant- and placebo-
treated depressed individuals or a difference between SSRIs
and either other types of antidepressants or placebo. Similar
suicide rates were seen among those randomly assigned to an
SSRI, a standard comparison antidepressant, or placebo in a
review of 48,277 depressed patients participating in the Food
and Drug Administration (FDA) reports of controlled clinical
trials for modern FDA-approved antidepressants (129).
Neither was there evidence that the risk of suicide or non-
fatal self-harm in adults prescribed SSRIs was higher than in
those prescribed tricyclic antidepressants in a UK study of
146,095 individuals with a first prescription of an antidepres-
sant for depression; there was some weak evidence of an
increased risk of non-fatal self-harm for current SSRI use
among those aged 18 or younger, although none committed
suicide (130). Epidemiological studies also have not sup-
ported the hypothesis that SSRIs may have a suicide-emergent
effect. Over a period of 9 years (1992–2000), treatment of
depressed individuals with SSRIs was not associated with an
increased risk of suicide in adults, children or adolescents in
Sweden (131).
However, there may be an association between the fall in
suicide rate and greater use of non-tricyclic antidepressants.
This is suggested by data from US where, from 1985 to 1999,
there was a decline by 13% in suicide rate and an increase of
over fourfold in antidepressant prescription rates, with the
increase mostly due to SSRIs (132). Data from all US indi-
viduals who committed suicide between 1996 and 1998
showed that prescriptions for SSRIs and other new-generation
non-SSRI antidepressants were associated with lower suicide
rates and that higher suicide rates in rural areas were asso-
ciated with fewer antidepressant prescriptions (133). This,
along with evidence to suggest that most of those who com-
mit suicide and who have major depressive disorder at the
time of death are either untreated or receiving subtherapeutic
Table 1 Antidepressants associated with reports of suspected with-
drawal reactions on the UK Adverse Drug Reactions On-line
Information Tracking
Drug substance
Number of UK reports
of withdrawal reactions
Paroxetine 1281
Venlafaxine 272
Fluoxetine 91
Sertraline 81
Citalopram 49
Bupropion 18
Clomipramine 18
Amitriptyline 15
Fluovoxamine 13
Mirtazapine 13
From: Medicines Control Agency UK 2002 ADROIT database – from the
top 20 medicines associated with reports of suspected withdrawal reactions.
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treatment delivery of antidepressants may potentially reduce
suicide rates.
Safety in Overdose
The SSRIs are considerably safer than tricyclic antidepressants
if taken in overdose. However, citalopram may be a possible
exception to the overall good safety profile of the SSRIs in
overdose.
In a review of 393 cases admitted to hospital for antide-
pressant overdose (no co-medication) from 1987 to 2003, 5-
HT syndrome was relatively common (14% of cases). Despite
this, all the SSRI were demonstrated to be relatively safe in
overdose and only citalopram was significantly associated with
QTc prolongation. The overall incidence of seizures was
1.9% and coma was 2.4% (35). In contrast, in a retrospective
review of 225 patients, citalopram was associated with a
significantly longer QT interval on ECG recording, but
mean QTc durations were not significantly different between
all drugs studied. Only venlafaxine and citalopram caused
seizures and were associated with admission to intensive care
units (38). In another study in 538 patients hospitalised due
to antidepressant overdose, SSRIs were shown to be less likely
to cause coma, to require admission to an intensive care unit
and prolong the QRS, but were more likely to cause 5-HT
toxicity than venlafaxine. Venlafaxine was comparable with
the tricyclics in terms of the risk of seizures and suicide (126).
CONCLUSION
The SSRIs (fluoxetine, sertraline, paroxetine, fluvoxamine
and citalopram), and also the SNRI venlafaxine, have become
a mainstay and first-line treatment for depression. The highly
specific actions of the SSRIs involving enhancement of pre-
dominantly serotonergic neurotransmission explain their ben-
eficial effects in depressed patients and patients with anxiety
disorders, while the lack of direct actions on other neuro-
transmitter systems is responsible for their superior safety
profile as compared with that of tricyclic antidepressants.
As a class, the SSRIs possess the following mild to moder-
ate adverse effects that do not require dose reductions or
discontinuation: erectile and ejaculatory dysfunction,
decreased libido, jitteriness, sweating, tachycardia, tremors,
anorexia, anxiety, diarrhoea, headache, insomnia and nausea.
Although a comparison of the adverse effects of SSRIs (and
venlafaxine) reveals little distinction among the agents, certain
differences are emerging. For example, the impact of SSRIs
on sexual function is perhaps the most deleterious side effect
from the point of view of the patient’s quality of life. In
contrast to several other SSRIs and also venlafaxine, evidence
suggests that fluvoxamine has beneficial effects on sleep in
depressed patients and a lower impact on bodyweight. In
terms of cardiotoxicity, it is established that the SSRIs are
more suitable than the tricyclic antidepressants for the treat-
ment of patients with cardiovascular disease due to a superior
cardiovascular safety profile. Fluvoxamine has been widely
studied in this regard, and evidence suggests it has no effect
on cardiovascular function in physically healthy patients and
is safe in patients with cardiovascular disease. Fluvoxamine
also has an excellent safety profile in frail elderly patients. A
discontinuation syndrome (involving disequilibrium, nausea,
vomiting, fatigue, sleep disturbances, lethargy, irritability and
agitation) may develop upon abrupt cessation of an SSRI.
This syndrome is more common with the SSRIs with shorter
half-lives and inactive metabolites. Finally, the SSRIs are
considerably more tolerable than tricyclic antidepressants in
overdose, and there is no conclusive evidence to suggest that
they are associated with an increased risk of suicide.
This review therefore suggests that while clinically signifi-
cant differences in efficacy amongst SSRIs do not exist, treat-
ment decisions need to be based on considerations such as
patient acceptability, patient history of prior response, toxicity
and cost. It is noteworthy in this respect that fluvoxamine has
a comparatively good profile in terms of adverse events. It has
a particularly low impact on sexual function (this may there-
fore reduce patient non-compliance) and an excellent safety
profile in the elderly.
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